Overview of Fuchs Endothelial Corneal Dystrophy (FECD)

Overview of Fuchs Endothelial Corneal Dystrophy (FECD)

Fuchs Endothelial Corneal Dystrophy is a chronic, inherited eye disorder that progressively damages the corneal endothelium—the inner layer of the cornea. It is marked by the development of guttae, corneal swelling (edema), and gradually diminishing vision, which can eventually result in corneal blindness. FECD occurs more commonly in women, and its prevalence varies across the seven major markets (7MM). Mutations in genes such as COL8A2, SLC4A11, TCF4, and ZEB1 have been associated with the disease’s onset.

Curious about the numbers? Dive into the data with our infographic : 

https://www.delveinsight.com/infographics/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

FECD Epidemiological Segmentation (2020–2034, 7MM)

• Total number of diagnosed prevalent cases
  
  

• Gender-based prevalence
  
  

• Age-specific cases
  
  

• Cases categorized by disease severity or grade
  
  

Epidemiological Insights
As of 2022, there were approximately 18.9 million diagnosed cases of FECD in the 7MM.

• The United States recorded around 6.5 million cases, a figure expected to grow as awareness improves.
  
  

• In the EU4 and the UK, about 9.2 million cases were reported.
  
  

• Japan had approximately 3 million cases in 2022, though this number is expected to decline by 2034 due to demographic trends.
  
  

See the bigger picture—get the full report : 

https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

FECD Market Overview
In 2022, the overall market for FECD in the 7MM was valued at approximately USD 850 million.

Market Growth Drivers:

• Increasing public and professional awareness of FECD and its impact on vision
  
  

• Advances in genetics and targeted therapeutic development
  
  

• Growing need for effective treatments due to the condition’s progressive nature
  
  

• Improvements in diagnostic technologies enabling earlier detection
  
  

• Enhanced advocacy efforts promoting research and access to care
  
  

Market Challenges:

• Few treatment options available for late-stage FECD
  
  

• High expenses associated with surgical solutions like corneal transplantation, limiting accessibility
  
  

• Difficulty in early detection due to slow disease progression
  
  

• Low awareness among clinicians and patients, especially in early or asymptomatic stages
  
  

• Regulatory obstacles delaying the adoption of innovative therapies
  
  

Understanding starts here—check out the infographic for key insights.

Emerging Therapies for FECD
Several promising drugs are under development, including:

• TTHX 1114
  
  

• Ripasudil (K-321)
  
  

• And others
  
  

Key Companies in the FECD Market
Leading industry players working on FECD therapies include:

• Kowa Pharmaceuticals
  
  

• Trefoil Therapeutics
  
  

• Alcon
  
  

• And others

Get the data. Get the insights. Get the report. Click Here